Akcea Therapeutics has received permission to make its unlicensed treatment for familial chylomicronemia syndrome (FCS) available to patients in the UK under the government’s early access to medicines scheme (EAMS) while the product undergoes evaluation for marketing throughout the EU.
Volanesorsen, an EU orphan designated drug for treating patients with the rare lipid disorder, was granted a positive scientific...